Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab
in patients ineligible for HCT-ASCT with Primary Central Nervous System Lymphoma (PCNSL)